OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Han on the Investigation of Neoadjuvant Therapy Plus a Dendritic Cell Vaccine in HER2+ Breast Cancer

July 27th 2023

Heather Han, MD, discusses initial safety and efficacy results from the phase 2 NATASHA trial in patients with early-stage HER2-positive breast cancer.

Dr Gillenwater on Phase 1 Data for ASP-1929 Plus Pembrolizumab in HNSCC

July 27th 2023

Ann M. Gillenwater, MD, discusses safety and efficacy data from the phase 1b/2 ASP-1929-181 trial evaluating the antibody-dye conjugate ASP-1929 in combination with pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma.

Dr Vaishampayan on Toxicities Associated With Various Treatments in RCC

July 27th 2023

Ulka Nitin Vaishampayan, MBBS, discusses toxicities associated with various treatment options for patients with renal cell carcinoma.

Dr Leary on Tovorafenib in Pediatric Low-Grade Glioma

July 26th 2023

Sarah E. S. Leary, MD, MS, discusses findings from the phase 2 FIREFLY-1 trial in pediatric patients with low-grade glioma.

Dr Agarwal on Future Questions to Address Following the TALAPRO-2 Trial in mCRPC

July 26th 2023

Neeraj Agarwal, MD, discusses future questions to be addressed following the phase 3 TALAPRO-2 trial evaluating the combination of talazoparib plus enzalutamide in patients with metastatic castration-resistant prostate cancer.

Dr Barata on the Relationship Between the Microbiome and Immunotherapy in RCC

July 26th 2023

Pedro Barata, MD, MSc, discusses the relationship between the gut microbiome and treatment with immunotherapy in patients with renal cell carcinoma.

Dr Anders on the Investigation of CCR4 Antagonists in Advanced Cancers

July 26th 2023

Robert Albert Anders, MD, PhD, discusses the rationale for developing CCR4 antagonists for use in patients with advanced cancers, including lymphoma and non–small cell lung cancer.

Dr O’Brien on Advances in Molecular Imaging in ER+ Breast Cancer

July 26th 2023

Sophia R. O'Brien, MD, discusses recent advances in the diagnosis and staging of estrogen receptor–positive metastatic breast cancer.

Dr Grieb on the Need for Novel Biomarkers in CRC

July 26th 2023

Brian C. Grieb, MD, PhD, discusses unmet needs for patients with colorectal cancer, including the identification of novel pan-CRC biomarkers for drug development.

Dr Matous on the Future Directions of CAR T-Cell Therapy in Multiple Myeloma

July 25th 2023

Jeffrey V. Matous, MD, discusses future directions of CAR T-cell therapy in multiple myeloma, highlighting the potential promise of novel targets beyond BCMA.

Dr Kirtane on the Design of the EVEREST-1 Trial Evaluating A2B530 in Solid Tumors

July 25th 2023

Kedar Kirtane, MD, discusses the design of the phase 1/2 EVEREST-1 trial, which is evaluating the autologous CAR T-cell therapy A2B530 in patients with advanced solid tumors.

Dr Munshi on the Background of the CARTITUDE-1 Trial in Multiple Myeloma

July 24th 2023

Nikhil C. Munshi, MD, discusses the background of the phase 1b/2 CARTITUDE-1 trial of ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma and highlights the specific patient population enrolled in the study.

Dr Williams on Remaining Unmet Needs in HER2+ Breast Cancer

July 24th 2023

Nicole O Williams, MD, discusses unmet needs for patients with HER2-positive breast cancer and potential future research directions in the space.

Dr Danilov on Treatment Considerations in High-Risk MCL

July 24th 2023

Alexey Danilov, MD, PhD, discusses considerations for varying treatment approaches in patients with high-risk mantle cell lymphoma.

Dr Patel on Safety Data and Biomarker Outcomes With Ide-Cel in High-Risk R/R Multiple Myeloma

July 21st 2023

Krina K. Patel, MD, MSc, discusses the safety profile of idecabtagene vicleucel in a subgroup of patients with high-risk, relapsed/refractory multiple myeloma, as well as findings with soluble BCMA levels from the phase 3 KarMMa-3 trial.

Dr Andre on the SOLSTICE Trial in mCRC

July 21st 2023

Thierry Andre, MD, discusses the efficacy of trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer and the safety profiles of the 2 arms of the phase 3 SOLSTICE trial.

Dr Sullivan on the Reduction of ctDNA With Tebentafusp in Metastatic Uveal Melanoma

July 21st 2023

Ryan J. Sullivan, MD, discusses the early reduction of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafusp and shares how these reductions could correlate with longer overall survival in patients with a best response of stable disease.

Dr Rogers on the NEO-Nal-IRI Trial in Pancreatic Adenocarcinoma

July 21st 2023

Sherise Rogers, MD, MPH, discusses the rationale for investigating irinotecan liposome injection plus 5-fluorouracil, leucovorin, and oxaliplatin in the preoperative treatment of patients with pancreatic adenocarcinoma.

Dr Falchi on the Use of Glofitamab in R/R LBCL

July 21st 2023

Lorenzo Falchi, MD, iscusses the use of glofitamab monotherapy in patients with relapsed/refractory large B-cell lymphoma.

Dr Krop on Age-Related Survival Outcomes With T-DXd in HER2+ Breast Cancer

July 21st 2023

Ian E. Krop, MD, PhD, discusses the use of fam-trastuzumab deruxtecan-nxki across age groups in the DESTINY Breast trials in patients with HER2-positive metastatic breast cancer.